No More Shame: The Menopause Series: Part 1 - Menopause - It’s Time We Talk About It and Why You Should Care | Part 2 - Menopause, Hormones, and the Questions We’re All Asking | Part 3 - Midlife Performance and Hormone Therapy | Part 4 - Rewriting the Change
What trusted medical research reveals about hormone therapy, its benefits, risks, and real-life decisions
1. Menopause as a Biological Transition and Lived Experience
Menopause represents a clearly defined biological milestone, yet its lived experience is far more complex than its clinical definition suggests. Medically, menopause is established after twelve consecutive months without menstruation, marking the end of ovarian reproductive function (World Health Organization [WHO], 2024). This definition provides clarity, but it does not fully capture the breadth of physiological and psychological changes that often accompany this stage.
For many women, menopause unfolds gradually, bringing with it a constellation of symptoms that extend beyond the cessation of menstruation. Vasomotor symptoms such as hot flashes, along with sleep disturbances, mood variability, joint discomfort, and cognitive changes, have been widely documented in clinical literature as common features of the menopausal transition (North American Menopause Society [NAMS], 2022). These changes may persist for years and, in some cases, become more pronounced in the postmenopausal period.
The variability of experience has contributed to a landscape of mixed messages and uncertainty. While some women are advised to accept these changes as a natural and inevitable process, others are cautioned against medical intervention, particularly hormone therapy. This divergence reflects not only differences in clinical interpretation but also the evolving nature of scientific understanding surrounding menopause and its management.
2. Hormone Therapy in Contemporary Medical Understanding
Menopausal hormone therapy, also referred to as hormone replacement therapy, remains one of the most extensively studied interventions in women’s health. It involves the administration of estrogen, with or without progesterone, to compensate for the decline in endogenous hormone production following menopause. According to contemporary clinical guidelines, hormone therapy is the most effective treatment for vasomotor symptoms associated with menopause (NAMS, 2022).
Beyond symptom relief, hormone therapy has been shown to improve overall quality of life in appropriately selected individuals. Clinical evidence has consistently demonstrated its role in alleviating night sweats, improving sleep patterns, and addressing genitourinary symptoms such as vaginal dryness and discomfort (NAMS, 2022; American College of Obstetricians and Gynecologists [ACOG], 2023). These benefits are particularly relevant for women whose daily functioning is significantly affected by menopausal symptoms.
At the same time, hormone therapy is not positioned as a universal solution. Contemporary medical frameworks emphasize individualized care, recognizing that the appropriateness of therapy depends on a woman’s age, time since menopause, symptom severity, and overall health profile. This shift reflects a broader movement in medicine toward personalization rather than generalized treatment approaches.
Image
3. Evidence-Based Benefits and Long-Term Health Considerations
The therapeutic benefits of hormone therapy have been consistently supported by large-scale studies and systematic reviews. Research demonstrated that hormone therapy remains the most effective intervention for reducing the frequency and severity of hot flashes and night sweats, which are among the most disruptive menopausal symptoms (NAMS, 2022). Improvements in sleep quality and mood regulation have also been reported, contributing to enhanced overall well-being.
In addition to symptomatic relief, hormone therapy plays a role in preserving bone health. Estrogen deficiency after menopause accelerates bone resorption, increasing the risk of osteoporosis and fractures. Clinical evidence indicated that hormone therapy slowed bone loss and reduced fracture incidence when initiated during the early postmenopausal period (ACOG, 2023; NAMS, 2022).
Long-term health outcomes, however, require careful interpretation. Findings from the Women’s Health Initiative provided critical insights into cardiovascular and thrombotic risks associated with hormone therapy, particularly when initiated later in life (Rossouw et al., 2013). Subsequent analyses refined these conclusions, showing that women who began therapy closer to menopause experienced more favorable outcomes, with no significant increase in all-cause mortality in appropriately selected populations (Manson et al., 2021; NAMS, 2022).
4. Understanding Risk Through Timing, Formulation, and Delivery
One of the most important advancements in menopause research is the recognition that risk is not uniform but influenced by timing, formulation, and route of administration. Evidence consistently supports what is often referred to as the “timing hypothesis,” which suggests that initiating hormone therapy within ten years of menopause onset or before the age of sixty is associated with a more favorable benefit-risk profile (NAMS, 2022; Manson et al., 2021).
The method by which hormones are delivered also plays a critical role in safety outcomes. Oral estrogen undergoes hepatic metabolism, which has been associated with an increased risk of venous thromboembolism in some populations. In contrast, transdermal estrogen bypasses the liver and has been associated with a lower risk of thrombotic events in observational and clinical studies (ACOG, 2023).
These distinctions have shifted clinical practice toward more nuanced prescribing. Rather than viewing hormone therapy as a single category, contemporary medicine recognizes multiple therapeutic pathways, each with distinct risk profiles. This evolution underscores the importance of individualized treatment planning guided by both evidence and patient context.
Image
5. The Role of Progesterone and Evolving Formulations
For women with an intact uterus, progesterone is required to counterbalance the effects of estrogen on the endometrial lining. Without this protective mechanism, unopposed estrogen increases the risk of endometrial hyperplasia and malignancy. The type of progesterone used, however, has emerged as an important factor in overall safety.
Research suggested that micronized progesterone, which is structurally similar to endogenous progesterone, may be associated with a more favorable cardiovascular and thrombotic profile compared to certain synthetic progestins (Stute et al., 2020). This distinction has gained increasing attention in recent clinical discussions, as formulation-specific differences may influence both safety and tolerability.
Emerging evidence also indicated that some women experienced improved sleep quality when micronized progesterone was administered at night, although this effect is not universal and requires further investigation. These findings highlight the growing sophistication of hormone therapy, moving beyond a one-size-fits-all approach toward more refined and patient-centered regimens.
6. Addressing Misconceptions and Reframing the Narrative
Despite decades of research, misconceptions about hormone therapy continue to shape public perception. One of the most persistent misunderstandings is the belief that hormone therapy is intended as a preventive treatment for chronic disease in all women. In reality, major clinical guidelines advise against its routine use for primary prevention without individualized risk assessment (NAMS, 2022).
Another common misconception is that initiating hormone therapy implies a lifelong commitment. Clinical practice does not support this view. Instead, therapy is intended to be periodically reassessed, with adjustments made based on evolving health status, symptom progression, and patient preference (ACOG, 2023).
Equally important is the recognition that hormone therapy does not replace foundational health practices. Nutrition, physical activity, resistance training, and cardiovascular risk management remain central to healthy aging. Hormone therapy may complement these practices for some women, but it does not substitute for them.
Image
7. Toward Informed and Individualized Decision-Making
The most consistent conclusion across contemporary research is that menopause management requires individualized care. No single intervention is appropriate for all women, and decisions regarding hormone therapy must consider personal medical history, symptom burden, and risk factors. This approach reflects a broader shift toward shared decision-making in clinical practice.
Consultation with a qualified healthcare professional remains essential. A comprehensive evaluation typically includes assessment of cardiovascular health, bone density, thrombotic risk, and family medical history, along with a detailed discussion of available therapeutic options (ACOG, 2023; NAMS, 2022). Such conversations allow for a balanced understanding of both benefits and risks.
This reframing moves the discussion away from binary thinking. Rather than asking whether hormone therapy is inherently good or bad, the more meaningful question becomes whether it is appropriate for a specific individual at a particular point in time.
8. Conclusion: Replacing Fear with Understanding
Menopause was once approached as a condition to be endured rather than understood. Contemporary medical science offers a more nuanced perspective, one that emphasizes informed choice, personalization, and quality of life. Hormone therapy remains a well-studied and effective option for many women when used appropriately within a clinical framework.
For others, alternative strategies may better align with their health profile and personal preferences. What matters most is the shift from fear-based decision-making to evidence-based understanding. Open dialogue, credible information, and professional guidance form the foundation of this transition.
In this context, menopause is no longer viewed solely as an endpoint, but as a phase that invites thoughtful engagement with one’s health. The goal is not to arrive at a universal answer, but to arrive at an informed and personally meaningful one.
Author’s Reflection
I write this not as a distant observer, but as a woman who has reached the stage where these questions become deeply personal. Menopause has prompted reflection, not only on biology, but on responsibility toward my own health and well-being. It has required me to listen carefully, question thoughtfully, and seek clarity where uncertainty once prevailed.
Engaging with credible research and meaningful conversations has reshaped how I view this transition. I no longer see hormone therapy as something to either accept or reject without thought, but as one of several options that deserve careful consideration. The responsibility lies not in choosing perfectly, but in choosing consciously.
There may never be a single correct answer, but there is always a thoughtful one. And sometimes, that is enough.
Disclaimer
The author is not a licensed medical practitioner and does not provide medical diagnosis, treatment, or professional health advice. This article is intended for educational purposes only and should not replace consultation with a qualified healthcare provider.
Image
Suggested Citation
Lendez, M. (2026). Menopause, hormones, and the questions we are all asking: What trusted medical research reveals about hormone therapy, its benefits, risks, and real-life decisions. Developed within the Ikigai-Bayanihan Purpose-Driven Retirement Framework.
About the Author
Dr. Mariza Lendez, DBA, is the developer of the Ikigai–Bayanihan Purpose-Driven Retirement Framework, a community-centered model that redefines aging through purpose, connection, and sustainable living. Her work focuses on helping individuals navigate aging with clarity, dignity, and informed decision making.
No More Shame: The Menopause Series
👉 Part 1: Menopause - It’s Time We Talk About It and Why You Should Care
👉 Part 2: Menopause, Hormones, and the Questions We’re All Asking
👉 Part 3: Midlife Performance and Hormone Therapy - What Current Evidence Shows About Women in Their 50s
👉 Part 4: Rewriting the Change - Your Menopause Roadmap to Balance and Vitality
References
American College of Obstetricians and Gynecologists. (2023). Hormone therapy for menopause.
Manson, J. E., Aragaki, A. K., Rossouw, J. E., et al. (2021). Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA, 325(4), 369–380.
North American Menopause Society. (2022). The 2022 hormone therapy position statement. Menopause, 29(7), 767–794.
Stute, P., Wildt, L., & Neulen, J. (2020). The impact of micronized progesterone on cardiovascular events. Climacteric, 23(5), 429–438.
World Health Organization. (2024). Menopause and healthy ageing.
Rossouw, J. E., et al. (2013). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 310(13), 1353–1368.
